How Long Does Hydroxychloroquine Stay in Your System?

Hydroxychloroquine has one of the longest elimination half-lives of any commonly prescribed medication, stretching beyond 40 days in most people. That means after you stop taking it, the drug lingers in your body for months, not days or weeks. Researchers have tracked it in blood and urine samples collected five months after a single dose. The reasons for this extraordinary persistence involve how deeply the drug buries itself in tissues throughout the body, and understanding that process matters whether you take it for lupus, rheumatoid arthritis, or are simply wondering how long it takes to fully clear.

The 40-Day Half-Life and What It Means in Practice

A drug’s half-life is the time it takes for the concentration in your body to drop by half. For hydroxychloroquine, that number sits around 40 to 50 days depending on the study and the individual.¹² To put that in perspective, most common medications have half-lives measured in hours. Even drugs considered “long-acting” usually clear within a few days of your last dose. Hydroxychloroquine plays by entirely different rules.

Because it takes roughly five half-lives for a drug to be essentially gone from the body, hydroxychloroquine can remain detectable for around six to eight months after discontinuation. That is not a theoretical estimate. Researchers have collected blood and urine samples for five months after a single dose specifically because the drug’s elimination phase is so prolonged.¹ If you have been taking it daily for months or years, the buildup in tissues means clearance could take even longer than it would after a single dose.

Why It Stays So Long

The persistence of hydroxychloroquine is not because your body struggles to break it down. The liver metabolizes it at a reasonable pace, and the kidneys clear it steadily. The real explanation is distribution: hydroxychloroquine has an enormous affinity for tissues. It leaves the bloodstream and lodges itself in organs, muscles, and other compartments throughout the body, then trickles back into the blood slowly over time.

Pharmacokinetic studies have calculated the drug’s volume of distribution at over 5,500 liters when measured from blood, and over 44,000 liters when measured from plasma.³ Those numbers are far larger than the volume of any actual human body, which tells you that the drug is concentrating in tissues at levels much higher than what circulates in the blood. The researchers who characterized this behavior put it clearly: the drug’s long residence in the body is driven primarily by this extensive tissue sequestration, not by slow clearance.³

Think of it like water soaking into a sponge. The drug rapidly distributes into your tissues after each dose, and it takes a long time for those tissues to release it back. The blood levels you see at any given moment are just the fraction trickling out, not the total amount stored.

How Your Body Breaks It Down

The liver handles the metabolic work. Several enzyme families are responsible for converting hydroxychloroquine into its breakdown products, with three enzymes playing the key roles: CYP3A4, CYP2D6, and CYP2C8.⁴ All three produce the same primary metabolites, desethylchloroquine and desethylhydroxychloroquine, though in varying amounts.⁴ Desethylhydroxychloroquine is itself pharmacologically active, meaning it still exerts biological effects in your body even after the parent drug has been partially broken down.⁵

This matters practically because drugs that interact with these same liver enzymes can speed up or slow down how quickly hydroxychloroquine is processed. If you are on other medications that compete for these enzymes, the effective half-life could shift. Hydroxychloroquine itself also inhibits CYP2D6, which means it can alter the metabolism of other drugs you take.⁴ The two-way nature of this interaction is something your prescriber should be tracking, especially if you are on a complex medication regimen.

Measuring Levels in Blood Versus Plasma

One peculiarity of hydroxychloroquine that trips up both patients and clinicians is that the concentration you measure depends heavily on what you measure it in. Whole blood levels run roughly twice as high as serum or plasma levels from the same blood draw. In one study of lupus patients, average whole blood concentrations were about 916 ng/mL while serum levels from the same patients averaged around 469 ng/mL.⁶ Another study found a comparable pattern, with whole blood levels averaging about 813 ng/mL versus roughly 436 ng/mL in serum and 362 ng/mL in plasma.⁷

The reason for the discrepancy is that hydroxychloroquine binds heavily to red blood cells and white blood cells. When you separate those cells out to get serum or plasma, you leave behind a large chunk of the drug. This is why most clinical guidelines recommend using whole blood for monitoring. If you see a lab result and are not sure what matrix was used, the number could be misleading. A serum level of 400 ng/mL and a whole blood level of 400 ng/mL represent very different situations.

How Kidney and Liver Disease Change the Timeline

Because hydroxychloroquine is partly eliminated through the kidneys, impaired kidney function slows its clearance and pushes blood levels higher. Research on lupus patients showed that blood levels clearly rose in those who developed kidney problems, whether looking at the most recent level before the decline or the average of all prior levels.⁸ This is the basis for the standard recommendation to reduce the dose in people with chronic kidney disease.

Liver disease also affects how long the drug sticks around, though the mechanism is different. Since the liver is responsible for metabolizing hydroxychloroquine into its breakdown products, liver cirrhosis impairs that process. Pharmacokinetic modeling has shown increased overall drug exposure in patients with liver cirrhosis.⁹ In older adults with healthy organs, drug exposure is similar to what younger adults experience. But when older patients have significant liver or kidney impairment, their simulated blood levels climb notably.¹⁰

The practical takeaway: if you have compromised kidney or liver function, hydroxychloroquine will stay in your system longer than the standard estimates suggest. Your doctor may need to adjust the dose, and drug monitoring becomes more important.

Melanin Binding and Why the Eyes Are Vulnerable

Hydroxychloroquine has a strong physical attraction to melanin, the pigment found in skin, hair, and critically, in the retinal pigment epithelium at the back of the eye.¹¹ This melanin binding creates a tissue-specific reservoir that keeps drug concentrations elevated in the retina long after blood levels have dropped. The adsorption is not unique to hydroxychloroquine; its close relative chloroquine does the same thing, but the two drugs differ in how tightly they bind, which helps explain why hydroxychloroquine is generally considered somewhat safer for the eyes.¹¹

“Somewhat safer” is a relative term, though. Long-term use of hydroxychloroquine can cause retinal toxicity, and the risk grows steadily with duration. Among patients who have taken the drug for more than five years, the overall prevalence of retinal toxicity is about 7.5%, rising to nearly 20% after 20 years of treatment.¹² Those numbers are higher than earlier estimates had suggested.¹³ Once retinal damage occurs, it can be irreversible and progressive even after the drug is stopped, precisely because the melanin-bound reservoir in the eye continues releasing drug locally.

This is why regular eye exams are recommended for anyone on long-term hydroxychloroquine. Current guidelines typically call for a baseline screening and then annual screening after five years of use, though your ophthalmologist may recommend starting earlier if you have other risk factors like kidney disease or a higher daily dose.

Therapeutic Drug Monitoring

Given hydroxychloroquine’s extreme variability from person to person, there has been growing interest in monitoring blood levels rather than relying on dose alone. In lupus patients, having therapeutic blood levels was associated with substantially lower rates of hospitalization and emergency visits. One study found that therapeutic levels were linked to about a two-thirds reduction in acute care use overall, and among subgroups with higher baseline healthcare needs, levels between 750 and 1,200 ng/mL were associated with a 95% reduction in acute care visits.¹⁴

Monitoring also catches non-adherence, which is common with any long-term medication. In pharmacokinetic simulations, a fully adherent patient taking 400 mg daily almost never shows a whole blood level below 200 ng/mL (the probability is under 0.1%). But when patients miss about 80% of their doses, roughly 60% of simulated blood levels fall below 200 ng/mL.¹⁵ In other words, a very low level is a reliable signal that doses are being missed. Ironically, the drug’s long half-life means that occasional missed doses do not tank levels the way they would with a short-acting drug, so the patients who show very low levels are likely missing doses routinely.

Despite these potential benefits, routine monitoring is not yet standard practice in most clinics, partly because of cost and insurance coverage concerns.¹⁴ This is an area where the evidence is ahead of clinical practice.

Body Weight and Drug Levels

You might expect that heavier people would need higher doses to reach the same blood levels, and many dosing guidelines do base the recommendation on body weight (typically 5 mg per kilogram of actual body weight as a maximum). But the relationship between weight and hydroxychloroquine blood levels is surprisingly weak. A study of pediatric lupus patients found that although dose-normalized concentrations appeared to decrease as body weight and BMI increased, the statistical fit was poor, with the relationship explaining only about 2-3% of the variation in drug levels.¹⁶

This means weight-based dosing is a rough starting point, but it does not reliably predict what any individual’s blood level will actually be. Genetics, kidney function, liver function, adherence patterns, and the drug’s own quirky tissue distribution all play roles that swamp the influence of body size. This adds to the case for monitoring blood levels rather than assuming the dose is getting you where you need to be.

How Long Until It Is Truly Out of Your System

If you are stopping hydroxychloroquine before surgery, switching medications, or simply want to know when it will no longer be having any effect, the answer depends on what you mean by “out.” Blood levels will drop to half of their steady-state value in roughly 40 to 50 days. By three months after your last dose, levels will be about a quarter of what they were. By six months, they will be low enough that most clinical effects have faded, though trace amounts may still be measurable. Complete elimination to the point where no analytical method could detect it may take closer to eight or nine months from the last dose of a chronic regimen.

Tissue levels lag even further behind blood levels. The drug trapped in melanin-rich tissues, stored in lysosomes throughout various organs, and lodged in red and white blood cells takes longer to release than what is freely circulating. For practical purposes like pregnancy planning, rheumatologists generally do not require a washout period for hydroxychloroquine because it is considered safe in pregnancy. But for concerns about drug interactions or side effects, the extended presence of the drug in tissues matters and should be discussed with your prescriber.

The kidneys are the primary exit route. A meaningful fraction of the drug leaves unchanged in urine, and the metabolites produced by the liver are also cleared renally. This dual dependence on the kidneys for both direct excretion and metabolite clearance is what makes kidney function so influential in determining how long the drug persists. If your kidneys are working well, clearance proceeds at the expected pace. If they are compromised, every phase of elimination slows, and the drug accumulates more than expected at any given dose.

What Standard Drug Tests Do and Do Not Detect

Hydroxychloroquine does not show up on standard workplace or forensic drug panels. Those tests screen for drugs of abuse like opioids, amphetamines, cannabis, and benzodiazepines. Hydroxychloroquine is an antimalarial and immunomodulatory drug with no abuse potential, so it is simply not included. You would need a specific assay ordered by a clinician to detect it. Such testing is done through specialized pharmacokinetic labs, often by liquid chromatography, and is typically ordered only in clinical contexts like therapeutic drug monitoring for lupus or checking adherence.

Hair testing for hydroxychloroquine is technically possible and has been used in research settings, but it is not part of routine clinical practice. Hair can retain drugs for considerably longer than blood or urine, so it offers a window into exposure history stretching back months. For hydroxychloroquine specifically, the drug’s already long blood half-life means that blood testing alone provides a reasonable picture of long-term exposure without needing hair samples in most cases.

Age and Pediatric Considerations

Children metabolize hydroxychloroquine differently than adults. Pharmacokinetic modeling shows that drug exposure at a given dose increases as age decreases, meaning younger children may experience higher concentrations relative to body size than adults do on the same weight-adjusted dose.¹⁰ This has prompted researchers to explore pediatric-specific dose adjustments that match the drug exposure seen in adults, rather than simply scaling by weight.

For older adults with normal organ function, the picture is reassuring: their drug exposure is largely comparable to that of younger healthy adults.¹⁰ The concern shifts when age-related decline in kidney or liver function enters the picture, since those are the systems responsible for clearing the drug. An otherwise healthy 70-year-old will handle hydroxychloroquine similarly to a 40-year-old. A 70-year-old with stage 3 kidney disease will not, and levels can climb steadily without dose adjustment. Periodic bloodwork to check kidney and liver function is part of routine care for anyone on long-term hydroxychloroquine, regardless of age, but it becomes especially relevant for older patients whose organ function may be quietly declining.

1
PubMed Central. Bioavailability of hydroxychloroquine tablets in healthy volunteers
2
Lupus. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases
3
PubMed Central. A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers
4
Drug Metabolism and Disposition. Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A in vitro
5
Journal of Clinical and Translational Hepatology. Impact of Liver Functions by Repurposed Drugs for COVID-19 Treatment
6
PubMed Central. Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherence
7
PubMed Central. Measurement of hydroxychloroquine in blood from SLE patients using LC-HRMS—evaluation of whole blood, serum, and serum as sample matrices
8
Arthritis & Rheumatology. Time to Renal Insufficiency Based on Prior Hydroxychloroquine Blood Levels
9
PubMed Central. Predicting Hydroxychloroquine Clearance in Healthy and Diseased Populations Using a Physiologically Based Pharmacokinetic Approach
10
Frontiers in Pharmacology. Development of a Physiologically Based Pharmacokinetic Model for Hydroxychloroquine and Its Application in Dose Optimization in Specific COVID-19 Patients
11
PubMed Central. Chloroquine and hydroxychloroquine binding to melanin: Some possible consequences for pathologies
12
Eye. Hydroxychloroquine retinopathy
13
PubMed Central. Hydroxychloroquine-induced Retinal Toxicity
14
PubMed Central. Therapeutic Hydroxychloroquine Blood Levels Are Associated With Fewer Hospitalizations and Possible Reduction of Health Disparities in Lupus
15
Lupus Science & Medicine. Interpreting hydroxychloroquine blood levels for medication non-adherence: a pharmacokinetic study
16
Lupus Science & Medicine. Pharmacokinetics of hydroxychloroquine in paediatric lupus: data from a novel, direct-to-family clinical trial